First HIV Vaccine for Africa Begins Trials.On January 27 IAVI IAVI International AIDS Vaccine Initiative (the International AIDS Vaccine Initiative A public-private partnership dedicated to producing a preventive vaccine against HIV infection, suitable for use in the most affected developing countries. To date, no such vaccine exists but scientific consensus suggests that its development is feasible. ) announced that the first HIV vaccine HIV vaccine AIDS As of mid-2005, there is no viable anti-HIV vaccine. See AIDS. designed specifically for Africa will begin human trials, after approval by the government of Kenya. From the IAVI announcement: "The preventive vaccine candidate is based upon subtype (programming) subtype - If S is a subtype of T then an expression of type S may be used anywhere that one of type T can and an implicit type conversion will be applied to convert it to type T. A of HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. , the most common strain in East Africa. The vaccine candidate is the product of an International AIDS Vaccine Initiative-funded partnership between the research teams of the Medical Research Council's Human Immunology Unit at Oxford University in the United Kingdom and the University of Nairobi The University of Nairobi also known as UON is the largest university in Kenya. Although its history as an institution goes back to 1956, it did not become an independent university until 1970 when the University of East Africa was split into three independent universities: . "It will be tested in a new, state of the art research facility at the University of Nairobi, which was officially opened by Kenya's Minister of Public Health, the Hon. Professor Sam K. Ongeri, in December. Recruitment for the trial began in December, and several of the 18 volunteers needed for the Phase I trial have already been screened. "The partners also announced a new agreement under which all existing and future patents covering the vaccine candidate will be owned jointly by the Medical Research Council, the University of Nairobi and the International AIDS Vaccine Initiative (IAVI). The partners agreed to use their patent ownership to help ensure access to a successful AIDS vaccine in Kenya and in other developing countries." In other vaccine news, on January 29 Bill Gates gave a $100 million "challenge grant" (to be matched by other contributions) to IAVI, to develop this or other AIDS vaccines. Internet company Yahoo! then contributed $5 million. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion